Content about Tazarotene

September 17, 2013

Stiefel has launched a new drug for treating acne, the company said on Tuesday.

NEW YORK — Stiefel has launched a new drug for treating acne, the company said Tuesday.

Stiefel, which is a subsidiary of British drug maker GlaxoSmithKline, announced the launch of Fabior (tazarotene) foam, which it called the only retinoid in a topical foam formulation for acne vulgaris in patients aged 12 and older.

The drug originally received Food and Drug Administration approval in May 2012.

May 23, 2012

The Food and Drug Administration has approved a new treatment for acne made by a GlaxoSmithKline subsidiary.

NEW YORK — The Food and Drug Administration has approved a new treatment for acne made by a GlaxoSmithKline subsidiary.

Stiefel announced the approval of Fabior (tazarotene) foam in the 0.1% strength, calling it the only retinoid in a topical foam for treating acne in patients ages 12 years and older.

"Stiefel is dedicated to meeting th needs of patients and dermatologists, and we believe Fabior foam will be an important treatment option for people with moderate-to-severe acne," Stiefel VP North America dermatology Jean-Christophe May said.

August 4, 2011

GlaxoSmithKline company Stiefel announced it is seeking approval for a facial acne treatment in patients ages 12 years and older.

RESEARCH TRIANGLE PARK, N.C. — GlaxoSmithKline company Stiefel announced it is seeking approval for a facial acne treatment in patients ages 12 years and older.

Stiefel said it has submitted a new drug application to the Food and Drug Administration for tazarotene foam. Tazarotene foam is subject to evaluation and approval by the regulatory authorities before it can be made available to physicians for prescribing to their appropriate patients, Stiefel said.